WBI Investments LLC Purchases 1,779 Shares of Organon & Co. (NYSE:OGN)

WBI Investments LLC boosted its position in shares of Organon & Co. (NYSE:OGN) by 3.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 61,967 shares of the company’s stock after acquiring an additional 1,779 shares during the period. WBI Investments LLC’s holdings in Organon & Co. were worth $894,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of OGN. Invesco Ltd. lifted its holdings in shares of Organon & Co. by 23.7% during the 3rd quarter. Invesco Ltd. now owns 10,240,630 shares of the company’s stock valued at $177,777,000 after purchasing an additional 1,963,682 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Organon & Co. by 10.0% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 10,211,008 shares of the company’s stock valued at $147,243,000 after buying an additional 930,708 shares during the last quarter. Sound Shore Management Inc. CT boosted its holdings in Organon & Co. by 35.2% in the fourth quarter. Sound Shore Management Inc. CT now owns 4,675,137 shares of the company’s stock worth $67,415,000 after acquiring an additional 1,216,522 shares in the last quarter. LSV Asset Management grew its stake in shares of Organon & Co. by 10.5% during the fourth quarter. LSV Asset Management now owns 3,349,579 shares of the company’s stock worth $48,301,000 after acquiring an additional 317,727 shares during the last quarter. Finally, Nordea Investment Management AB increased its holdings in shares of Organon & Co. by 2,016.0% during the fourth quarter. Nordea Investment Management AB now owns 3,128,810 shares of the company’s stock valued at $44,648,000 after acquiring an additional 2,980,945 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Stock Performance

OGN traded down $0.27 during trading on Thursday, reaching $21.69. 458,931 shares of the company’s stock were exchanged, compared to its average volume of 2,603,642. The company has a debt-to-equity ratio of 181.35, a current ratio of 1.65 and a quick ratio of 1.15. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $24.08. The company’s fifty day simple moving average is $19.03 and its 200-day simple moving average is $16.32. The stock has a market capitalization of $5.58 billion, a P/E ratio of 5.37, a price-to-earnings-growth ratio of 0.95 and a beta of 0.81.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 13th. Investors of record on Monday, May 13th will be issued a dividend of $0.28 per share. The ex-dividend date is Friday, May 10th. This represents a $1.12 annualized dividend and a dividend yield of 5.16%. Organon & Co.’s dividend payout ratio (DPR) is presently 27.38%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on OGN. The Goldman Sachs Group boosted their target price on shares of Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Piper Sandler boosted their price objective on shares of Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Monday, April 29th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.